<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193189</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5379</org_study_id>
    <secondary_id>38569</secondary_id>
    <nct_id>NCT04193189</nct_id>
  </id_info>
  <brief_title>B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B</brief_title>
  <acronym>BEe-HIVe</acronym>
  <official_title>B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B&#xD;
      in two study populations living with HIV: prior HBV vaccine recipients who are deemed&#xD;
      non-responders and individuals who are naïve to HBV vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase III/IV study will evaluate the response to and safety of the HBV vaccine&#xD;
      HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are&#xD;
      deemed non-responders (Group A) and individuals who are naïve to HBV vaccination (Group B).&#xD;
&#xD;
      Group A (HBV vaccine non-responders)&#xD;
&#xD;
      The study is designed as an open-label three-arm study to evaluate whether:&#xD;
&#xD;
        1. HEPLISAV-B vaccination given as a two-dose series achieves non-inferior seroprotection&#xD;
           response (SPR) compared to standard dose ENGERIX-B.&#xD;
&#xD;
        2. HEPLISAV-B vaccination given as a three-dose series achieves superior SPR proportion&#xD;
           compared to standard dose ENGERIX-B.&#xD;
&#xD;
      Participants are randomized in 1:1:1 ratio to the following study arms, stratified by sex at&#xD;
      birth (male vs. female) and diabetes diagnosis status (yes vs. no):&#xD;
&#xD;
        -  Arm 1: Two doses of HEPLISAV-B at weeks 0 and 4.&#xD;
&#xD;
        -  Arm 2: Three doses of HEPLISAV-B at weeks 0, 4, and 24.&#xD;
&#xD;
        -  Arm 3: Three doses of ENGERIX-B at weeks 0, 4, and 24.&#xD;
&#xD;
      The target sample size in Group A is 561 participants, 187 participants in each arm.&#xD;
&#xD;
      Group B (Naïve to HBV vaccination)&#xD;
&#xD;
      Group B study is a single arm evaluation of vaccine response and safety of three doses of&#xD;
      HEPLISAV-B. The target sample size is 73 participants.&#xD;
&#xD;
      All participants will remain on their non-study-provided antiretroviral therapy (ART)&#xD;
      throughout the study. Participants in both groups will attend several study visits through&#xD;
      Week 72. Visits may include physical examinations and blood collection. For 7 days after each&#xD;
      vaccination, participants will record temperature and any reactions they have to the vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">March 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection response defined as hepatitis B virus surface antibody (HBsAb) ≥10 mIU/mL</measure>
    <time_frame>Week 12 in Group A, Arm 1, Week 28 in Group A, Arms 2 and 3 and in Group B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Adverse events (AEs)</measure>
    <time_frame>From vaccination initiation to study discontinuation (Week 72 or premature discontinuation)</time_frame>
    <description>DAIDS AE Grading Table (Version 2.1) will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection response defined as HBsAb ≥10 mIU/mL</measure>
    <time_frame>Weeks 4, 8, 12, 24, 28, 32, 48, 52 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb titer</measure>
    <time_frame>Weeks 4, 8, 12, 24, 28, 32, 48, 52 and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Grade ≥2 AEs within 4 weeks after each injection</measure>
    <time_frame>From vaccination initiation to Week 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">634</enrollment>
  <condition>HIV Infection</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A, Arm 1: HEPLISAV-B (two injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A, Arm 2: HEPLISAV-B (three injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A, Arm 3: ENGERIX-B (three injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: HEPLISAV-B (three injections)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV-B</intervention_name>
    <description>Administered by IM injection</description>
    <arm_group_label>Group A, Arm 1: HEPLISAV-B (two injections)</arm_group_label>
    <arm_group_label>Group A, Arm 2: HEPLISAV-B (three injections)</arm_group_label>
    <arm_group_label>Group B: HEPLISAV-B (three injections)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ENGERIX-B</intervention_name>
    <description>Administered by IM injection</description>
    <arm_group_label>Group A, Arm 3: ENGERIX-B (three injections)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria, Groups A and B&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  On current HIV-1 antiretroviral therapy (ART)&#xD;
&#xD;
          -  CD4+ T-cell count ≥100 cells/mm^3&#xD;
&#xD;
          -  HIV-1 RNA &lt;1000 copies/mL&#xD;
&#xD;
        Inclusion Criteria, Group A only&#xD;
&#xD;
          -  Serum Hepatitis B antibody &lt;10 mlU/mL, non-reactive (negative), or indeterminate&#xD;
&#xD;
          -  Documentation of HBV vaccination &gt;168 days prior to study entry&#xD;
&#xD;
        Inclusion Criterion, Group B only&#xD;
&#xD;
          -  Serum Hepatitis B antibody non-reactive (negative) within 45 days prior to study entry&#xD;
&#xD;
        Exclusion Criteria, Groups A and B&#xD;
&#xD;
          -  Infection or prior exposure to HBV&#xD;
&#xD;
          -  Serum HBsAb level ≥10 mlU/mL or positive at screening or any other time prior to&#xD;
             screening&#xD;
&#xD;
          -  Presence of any active or acute AIDS-defining opportunistic infections&#xD;
&#xD;
          -  Solid organ transplantation&#xD;
&#xD;
          -  History of ascites, encephalopathy, or variceal hemorrhage&#xD;
&#xD;
          -  Diagnosis of chronic kidney disease (CKD) stage G4&#xD;
&#xD;
          -  Cancer diagnosis within 5 years&#xD;
&#xD;
          -  Currently receiving chemotherapy&#xD;
&#xD;
          -  Chronic use and/or receipt of systemically administered immunosuppressive&#xD;
&#xD;
          -  Known allergy/sensitivity or any hypersensitivity to any HBV vaccine or yeast&#xD;
&#xD;
          -  Active, serious infection other than HIV-1&#xD;
&#xD;
          -  Receipt of any inactivated virus vaccine within 14 days&#xD;
&#xD;
          -  Receipt of any of the following within 45 days prior to study entry:&#xD;
&#xD;
               -  Live virus vaccine&#xD;
&#xD;
               -  Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage&#xD;
                  colony-stimulating factor (GM-CSF)&#xD;
&#xD;
               -  Any other investigational medicinal agent&#xD;
&#xD;
          -  Receipt of immunoglobulin or blood products within 90 days prior to study entry&#xD;
&#xD;
          -  Receipt of an injection of DNA plasmids or oligonucleotides within 60 days prior to&#xD;
             study entry&#xD;
&#xD;
        Exclusion Criteria, Group A only&#xD;
&#xD;
          -  Hepatitis B virus vaccination ≤168 days prior to study entry&#xD;
&#xD;
          -  Receipt of HEPLISAV-B vaccine at any time prior to study entry&#xD;
&#xD;
        Exclusion Criterion, Group B only&#xD;
&#xD;
          -  Known HBV vaccination prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth E. Sherman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cincinnati CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen Marks, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Weill Cornell Chelsea CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faye Heard, M.P.H.</last_name>
      <phone>205-996-2371</phone>
      <email>heaths@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035-4709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleen Khodabakhshian</last_name>
      <phone>310-557-9027</phone>
      <email>akhodabakhshian@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hendrickx, R.N.</last_name>
      <phone>619-543-6968</phone>
      <email>smhendrickx@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ucsf Hiv/Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Gomez</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>106</phone_ext>
      <email>elvira.gomez@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Guerrero</last_name>
      <phone>424-201-3000</phone>
      <phone_ext>7318</phone_ext>
      <email>mguerrero@lundquist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Fiorillo, M.S.P.H.</last_name>
      <phone>303-724-5931</phone>
      <email>suzanne.fiorillo@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whitman-Walker Health CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Avery A. Wimpelberg, B.A., CCRC</last_name>
      <phone>202-797-3589</phone>
      <email>AWimpelberg@whitman-walker.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308-2012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ericka Patrick, M.S.N.</last_name>
      <phone>404-616-6313</phone>
      <email>erpatri@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baiba Berzins, M.P.H.</last_name>
      <phone>312-695-5012</phone>
      <email>Baiba@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Mall, R.N.</last_name>
      <phone>312-942-5865</phone>
      <email>mark_mall@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Becker, PA-C</last_name>
      <phone>410-614-4036</phone>
      <email>rbecke22@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Sbrolla, R.N., B.S.N., A.C.R.N.</last_name>
      <phone>1-617-726-5598</phone>
      <email>asbrolla@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl E. Keenan, R.N.</last_name>
      <phone>617-732-5635</phone>
      <email>cKennan@BWH.Harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael K. Klebert</last_name>
      <phone>314-747-1098</phone>
      <email>mklebert@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School Clinical Research Center CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rondalya DeShields, R.N., B.S.N.</last_name>
      <phone>973-972-3729</phone>
      <email>deshierd@njms.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaun R. Barcavage, N.P.</last_name>
      <phone>646-647-6247</phone>
      <email>srb4001@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Palmer, P.A.-C</last_name>
      <phone>212-342-2958</phone>
      <email>sp500@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Uptown CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fry, M.S.N., FNP</last_name>
      <phone>212-746-4166</phone>
      <email>ref2007@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Adult HIV Therapeutic Strategies Network CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hulse</last_name>
      <phone>585-275-0529</phone>
      <email>susan_hulse@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Straub, B.S.N., M.P.H., R.N.</last_name>
      <phone>919-843-9975</phone>
      <email>bstraub@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greensboro CRS</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Epperson, R.N., B.S.N., CRC</last_name>
      <phone>1-336-832-3262</phone>
      <email>kim.epperson@conehealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Clinical Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Kohrs, R.N., B.S.N.</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Clinical Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Baum, R.N.</last_name>
      <phone>216-844-2546</phone>
      <email>jb@clevelandactu.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Watson, B.S.N., R.N.</last_name>
      <phone>614-293-5856</phone>
      <email>kathy.watson@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Therapeutics CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Baer, M.B., M.B.A.</last_name>
      <phone>215-349-5023</phone>
      <email>Baer2@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn R. Weinman</last_name>
      <phone>412-383-1748</phone>
      <email>drw38@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Venderbilt Therapeutics (VT) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>47183</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly O. Woodward, M.S.N., R.N.</last_name>
      <phone>615-936-8516</phone>
      <email>beverly.o.woodward@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center CRS</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Rogers, CCRC</last_name>
      <phone>972-807-7370</phone>
      <email>lauren.rogers@prismntx.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria L. Martinez</last_name>
      <phone>713-500-6718</phone>
      <email>Maria.L.Martinez@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-9929</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Jonsson, EMBA</last_name>
      <phone>206-744-8886</phone>
      <email>cjonsson@u.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brenda W. Hoagland, M.D.</last_name>
      <phone>55-21-38659122</phone>
      <email>brenda.hoagland@ini.fiocruz.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS</name>
      <address>
        <city>Port-au-Prince</city>
        <zip>HT-6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yvetot Joseph, MD</last_name>
      <phone>509-36832867</phone>
      <email>yvetotjoseph@gheskio.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS</name>
      <address>
        <city>Port-au-Prince</city>
        <zip>HT-6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samuel Pierre, M.D.</last_name>
      <phone>509-29-426327</phone>
      <email>spierre@gheskio.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chennai Antiviral Research and Treatment (CART) CRS</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faith E. Samson</last_name>
      <phone>91-44-39106811</phone>
      <email>beulah@cartcrs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS</name>
      <address>
        <city>Kericho</city>
        <state>Rift Valley</state>
        <zip>20200</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samwel K. Chirchir, R.N., B.Sc.</last_name>
      <phone>254-52-2036100</phone>
      <email>Samwel.Chirchir@usamru-k.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blantyre CRS</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dumisile Huwa</last_name>
      <phone>265-1811885</phone>
      <email>dhuwa@jhu.medcol.mw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC)</name>
      <address>
        <city>Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria T Gler, MD</last_name>
      <phone>63-9178230431</phone>
      <email>tarcelasg@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Helen Joseph Hospital CRS (Wits HJH CRS), Perth Road, Westdene</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Reyneke</last_name>
      <phone>27-11-2768817</phone>
      <email>areyneke@witshealth.co.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Durban International Clinical Research Site CRS</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosie Mngqibisa, MBChB, M.B.B.S.</last_name>
      <phone>27-31-2611095</phone>
      <email>rosie@ecarefoundation.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soweto ACTG CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Soweto</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Peters</last_name>
      <phone>27-119899700</phone>
      <email>petersd@phru.co.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre (TRC-ARC) CRS</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Parawee Thongpaeng</last_name>
      <phone>662-6523040</phone>
      <phone_ext>106</phone_ext>
      <email>parawee.t@hivnat.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daralak Tavomprasit, R.N., M.Sc.</last_name>
      <phone>66-5-3936148</phone>
      <phone_ext>176</phone_ext>
      <email>daralak@rihes.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yen Hoa Health Clinic CRS</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tran Ha</last_name>
      <phone>84-29-12785886</phone>
      <email>vietha@live.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milton Park CRS</name>
      <address>
        <city>Milton Park</city>
        <state>Harare</state>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela G Mukwekwerere</last_name>
      <phone>263-772951820</phone>
      <email>pmukwekwerere@uz-ctrc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Haiti</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
    <country>Vietnam</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.</ipd_time_frame>
    <ipd_access_criteria>With whom?&#xD;
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.&#xD;
For what types of analyses?&#xD;
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.&#xD;
By what mechanism will data be made available?&#xD;
Researchers may submit a request for access to data using the AIDS Clinical Trials Group &quot;Data Request&quot; form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

